Alimera Sciences Inc

Alimera Sciences — Investor Presentation (March 2016)

21 slides from Alimera Sciences's investor presentation, Mar 8, 2016

  1. Slide 1: Exhibit 99.1

    Exhibit 99.1

  2. Slide 2: Investor Presentation March 2016

    Investor Presentation © March 2016 ALIME SCIENCES

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement 1995, regardi the y * and that ILUVIEN’ will project to be 16.6% of the projected therapy Juding factor that could del: ‘h “anticipate, “believe,” “estimate,” “expect,” “intend,” “may” “plan, “contemplate,” “predict,” “project. “target, “likely,” ‘potential “continue,” “ongoing

  4. Slide 4: Commercial Stage DME Corticosteroid Treatment

    Commercial Stage DME Corticosteroid Treatment Commercialization of ILUVIEN® in 2015 REVENUE GROWTH +167% 2B GLOBAL MARKET "sm OPPORTUNITY * 2015 Revenue growth of 167% * Significant Benefits to the current standard of ya $9.7M 4 $8.4M + Expanding Distribution Platform * Strong Senior Management Team

  5. Slide 5: Management Team

    Management Team Strong Senior Management Team with +100 Years of Ophthalmology Experience }) NOVARTIS =ALLERGAN BAUSCH+LOMB (a 3) sanofi aventis (Pfizer PeG © AANA

  6. Slide 6: Product Overview

    Product Overview A Unique Treatment of Diabetic Macular Edema (DME)

  7. Slide 7: Debilitating Permanent Damage of DME

    Debilitating Permanent Damage of DME Primary Cause of Vision Loss in Diabetic Patients 00% DME PATIENTS THAT END UP WITH VISION OF 20/60 OR WORSE” -* ‘ + Leaky blood vessels in the macula cause the retina to swell + Causes blurred vision in early stage, over long term may cause cumulative damage. AL

  8. Slide 8: ILUVIEN®: Unique DME Treatment

    ILUVIEN®: Unique DME Treatment Consistent Control for Patients Who Require Persistent Treatment uuu PROVEN TO LAST 36 MONTHS 12 times longer than the next comparable long-acting product ae CONTINUOUS DRUG DELIVERY Eliminates the inconsistent treatment of other, more frequently dosed options PATIENT

  9. Slide 9: ILUVIEN®: Unique DME Treatment

    ILUVIEN®: Unique DME Treatment Consistent Control for Patients Who Require Persistent Treatment

  10. Slide 10: Consistent Delivery With Sustained Effect

    Consistent Delivery With Sustained Effect ILUVIEN® Delivers More Efficiently than Competitive Products OZURDEX® EUROPEAN MEDICINES. “~~ 22%700(erun0e ILUVIEN® PHASE) ——22s/trractmazrournen a Og Pactnn328) AGENCY ASSESSMENT REPORT = =~ srom CLINICAL TRIALS (FAME) —+ stom $ | __ Change From Baseline (

  11. Slide 11: Significant Market Opportunity

    Significant Market Opportunity ~~

  12. Slide 12: Worldwide Market Opportunity

    Worldwide Market Opportunity AIWUS. 57500 PATENTS US ence 17% sme US INCIDENCE GROWTH 575,000 EXISTING DME PATIENTS 59% EU £836,000 PATIENTS. o ALIA

  13. Slide 13: Cost-Effective Treatment Option

    Cost-Effective Treatment Option Calculated based on the midpoint of annual labeled injections range, 3-year treatment period $27,750 $17,550 7 = a 1 LUVIEN Ozurdery QyEYLEA LucentS ALIME

  14. Slide 14: Growing Commercial Footprint

    Growing Commercial Footprint Strategic Expansion into New, International Markets

  15. Slide 15: Global Commercialization Status

    Global Commercialization Status ILUVIEN®'s Commercialization Footprint is Large, and we are Making Inroads to New Territory Bi warcereo §=—- I apPRoven Portugal ® AU

  16. Slide 16: Supplemental Growth With License Deals

    Supplemental Growth With License Deals Creating Additional Growth Opportunities Through Licensing Agreements Middle East = Australia © Au

  17. Slide 17: Persistent US Account Growth

    Persistent US Account Growth Driven by Salesforce Execution 3/7 SALES EXECUTIVES OFFICIAL US LAUNCH - 3 1 2 ACCOUNTS AT a» 4 YEAR-END 3 gy J JAN FEB OMAR) APR) MAY JUN AUG SEPT) =OCT_=—S NOW ALI

  18. Slide 18: Solid Execution Within Years of Launch

    Solid Execution Within 2 Years of Launch Financial Overview ee

  19. Slide 19: Increasing Commercial Sales

    Increasing Commercial Sales

  20. Slide 20: Strong Top-Line Performance

    Strong Top-Line Performance $22.4M Pi consounaren revenue Bi esrevenue $15.2M 2015 US REVENUE $5.8M Eo $7.3M 2015 EU REVENUE tT 40.15 REVENUE 2015 FULL-YEAR REVENUE o ALIA

  21. Slide 21: $2 Billion Market Opportunity

    $2 BILLION MARKET OPPORTUNITY Growing with global diabetes epidemic - 575,000 U.S. & 835,000 European DME sufferers TARGET STRATEGIC MARKET OPPORTUNITIES Penetrate STRONG BALANCE SHEET Supported by $31 million of cash as reported 12/31/15 CONTINUED LONG-TERM GROWTH IVIEN® peak sales potential exceed

Alimera Sciences — Investor Presentation (March 2016) on 6ix